Boston Scientific Corporation
BSX
$51.11
$0.651.29%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 7.53% | 11.58% | 15.90% | 20.34% | 22.84% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.53% | 11.58% | 15.90% | 20.34% | 22.84% |
| Cost of Revenue | -2.73% | 9.20% | 9.42% | 16.55% | 29.09% |
| Gross Profit | 12.49% | 12.67% | 18.99% | 22.06% | 20.03% |
| SG&A Expenses | 5.07% | 11.52% | 13.77% | 11.46% | 18.67% |
| Depreciation & Amortization | 3.56% | 5.94% | 1.33% | 9.76% | 5.63% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.89% | 10.87% | 12.57% | 15.01% | 24.00% |
| Operating Income | 32.13% | 14.41% | 31.77% | 46.24% | 18.02% |
| Income Before Tax | 12.65% | 44.47% | 19.86% | 40.21% | 124.05% |
| Income Tax Expenses | 6.16% | -232.33% | 30.43% | -8.50% | 48.98% |
| Earnings from Continuing Operations | 13.84% | 99.26% | 19.43% | 60.98% | 146.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 0.00% | 0.00% | -50.00% | -- | 0.00% |
| Net Income | 13.80% | 98.96% | 18.94% | 60.98% | 145.99% |
| EBIT | 32.13% | 14.41% | 31.77% | 46.24% | 18.02% |
| EBITDA | 25.18% | 12.76% | 23.55% | 35.94% | 15.23% |
| EPS Basic | 14.56% | 97.92% | 18.24% | 59.97% | 144.44% |
| Normalized Basic EPS | 35.68% | 19.93% | 31.34% | 42.33% | 14.96% |
| EPS Diluted | 15.09% | 100.00% | 18.54% | 59.97% | 140.91% |
| Normalized Diluted EPS | 36.48% | 20.44% | 31.62% | 42.42% | 14.96% |
| Average Basic Shares Outstanding | -0.66% | 0.52% | 0.58% | 0.61% | 0.63% |
| Average Diluted Shares Outstanding | -1.25% | 0.13% | 0.38% | 0.54% | 0.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |